Therapeutic research in untreated acute promyelocytic leukemia

Leukemia

Volumn 19, Issue 6, 2005, Pages 913-915

  Estey, E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; CD33 ANTIGEN; CYTARABINE; FLT3 LIGAND; GEMTUZUMAB OZOGAMICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER REGRESSION; CANCER RELAPSE; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG TARGETING; DRUG WITHDRAWAL; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTE COUNT; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; METHODOLOGY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; NOTE; REMISSION; RISK FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; REMISSION INDUCTION; RISK FACTORS;

EID: 20844458110     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403767     Document Type: Article

References (16)

1. Schlenk R, Germing U, Hartmann F, Glasmacher A, Fischer J, del Valle y Fuentes F, et al., for the AML Study Group. High dose cytarabine and mitoxantrone in consolidation therapy for acure promyelocytic leukemia. Leukemia 2005; 19: 978-983.
2. Fenauax P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, et al., for the European APL Group. A randomized comparison of all trans-retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94: 1192-1200.
3. Avvisati G, Petti M, Lo-Coco F, Vegna M, Amadori S, Baccarani M, et al., for the GIMEMA Group. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002; 100: 3141-3146.
4. Sanz M, Lo Coco F, Martín G, Avvisati G, Rayón C, Barbui T, for the Spanish PETHEMA and Italian GIMEMA Copeartive Groups. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253.
5. Lo Coco F, Diverio D, Avvisati G, Petti M, Meloni G, Pogliani E et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999; 94: 2225-2229.
6. Estey E. Treatment options for relapsed APL. Best Pract Res Clin Haematol 2003; 16: 521-534.
7. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, et al., for the GIMEMA and AEIOP Groups. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin therapy. Blood 1997; 90: 1014-1021.
8. Sanz M, Martín G, González M, León A, Rayón C, Rivas C et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-1243.
9. Soignet S, Frankel S, Douer D, Tallman M, Kantarjian H, Calleja E et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
10. Jurcic J, DeBlasio T, Dumont L, Yao T, Scheinberg D. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res 2000; 6: 372-380.
11. Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L, All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992; 6 (Suppl 1): 64-66.
12. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci USA 2004; 101: 5328-5335.
13. Ades L, Chevret S, De Botton S, Thomas X, Dombret H, Beve B, et al., for the European APL Group. Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience. Leukemia 2005; 19: 230-233.
14. Sanz M, Vellenga E, Rayón C, Díaz-Mediavilla J, Rivas C, Amutio E et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004; 104: 3490-3493.
15. Estey E, Giles F, Beran M, O'Brien S, Pierce S, Faderl S et al. Experience with gemtuzumab ozogamycin ('mylotarg') and all- trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002; 99: 4222-4224.
16. Lo Coco F, Cimino G, Breccia M, Noguera N, Diverio D, Finolezzi E et al. Gemtuzumab ozogamicin (mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood 2004; 104: 1995-1999.